Antileukotriene therapy for the relief of sinus symptoms in aspirin triad disease

Ear, Nose and Throat Journal

Volumn 78, Issue 8, 1999, Pages 604-616

  Ulualp, Seckin O ^a   Sterman, Bruce M ^a   Toohill Md, Robert J ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MEMBRANE PHOSPHOLIPID; NONSTEROID ANTIINFLAMMATORY AGENT; ZAFIRLUKAST; ZILEUTON;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HUMAN; MALE; NOSE POLYP; QUESTIONNAIRE; SINUSITIS; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0032782372     PISSN: 01455613     EISSN: None     Source Type: Journal    
DOI: 10.1177/014556139907800818     Document Type: Article

References (37)

1. McFadden EA, Woodson BT, Fink JN, Toohill RJ. Surgical treatment of aspirin triad sinusitis. Am J Rhinol 1997;11:263-70.
2. Jung TT, Juhn SK, Hwang D, Stewart R. Prostaglandins, leukotrienes, and other arachidonic acid metabolites in nasal polyps and nasal mucosa. Laryngoscope 1987:97:184-9.
3. Smith WL, Borgeat P, Fitzpatrick FA. The eicosanoids: Cyclooxygenase, lipoxygenase, and epoxygenase pathways. In: Vance DE, ed. Biochemistry of Lipids, Lipoproteins, and Membranes. Amsterdam: Elsevier, 1991.
4. Fischer AR, Rosenberg MA, Lilly CM, et al. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol 1994;94:1046-56.
5. Drazen JM, Austen KF, Lewis RA, et al. Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci U S A 1980;77:4354-8.
6. Marom Z, Shelhamer JH, Bach MK, et al. Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982;126:449-51.
7. Dahlen SE, Bjork J, Hedqvist P, et al. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: In vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci USA 1981;78:3887-91.
8. Hoover RL, Karnovsky MJ, Austen KF, et al. Leukotriene B4 action on endothelium mediates augmented neutrophil/endothelial adhesion. Proc Natl Acad Sci U S A 1984;81:2191-3.
9. Bisgaard H, Pedersen M. SRS-A leukotrienes decrease the activity of human respiratory cilia. Clin Allergy 1987;17:95-103.
10. Knorr B, Matz J, Bernstein JA, et al Montelukast for chronic asthma in 6-to 14-year-old children: A randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 1998;279:1181-6.
11. Krell RD, Aharony D, Buckner CK, et al. The preclinical pharmacology of ICI 204,219: A peptide leukotriene antagonist. Am Rev Respir Dis 1990;141:978-87.
12. Rubin P, Dube L, Braeckman R, et al. Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase Agents Actions Suppl 1991;35.103-16.
13. Carter GW, Young PR, Albert DH, et al. 5-Lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther 1991;256:929-37.
14. Knapp HR. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med 1990;323:1745-8.
15. Hirschberg VGS. Mitteilung uber einen Fall von Nebenwirkung des Aspirin A case report on the side effects of aspirin. Dtsch Med Wochenschr 1902;28:416 and Allergy Proc 1990;11:249-50.
16. Hirschberg VGS. Mitteilung uber einen Fall von Nebenwirkung des Aspirin A case report on the side effects of aspirin. Dtsch Med Wochenschr 1902;28:416 and Allergy Proc 1990;11:249-50.
17. Lockey RF, Rucknagel DL, Vanselow NA. Familial occurrence of asthma, nasal polyps and aspirin intolerance Ann Intern Med 1973;78:57-63.
18. Falhers CJ. Familial coincidence of asthma, aspirin intolerance and nasal polyposis. Ann Allergy 1974;32:65-9.
19. Settipane GA, Pudupakkam RK. Aspirin intolerance. III. Subtypes, familial occurrence, and cross-reactivity with tartarazine. J Allergy Clin Immunol 1975;56:215-21
20. Zeitz HJ. Bronchial asthma, nasal polyps, and aspirin sensitivity: Samter's syndrome. Clin Chest Med 1988;9:567-76.
21. Christie PE, Tagari P, Ford-Hutchinson AW, et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991;143:1025-9.
22. Smith CM, Hawksworth RJ, Thien FC, et al. Urinary leukotriene E4 in bronchial asthma. Eur Respir J 1992;5:693-9.
23. Kowalski ML, Sliwinska-Kowalska M, Igarashi Y, et al. Nasal secretions in response to acetylsalicylic acid J Allergy Clin Immunol 1993;91:580-98.
24. Kowalski ML. Aspirin sensitive rhinosinusitis and asthma. Allergy Proc 1995;16:77-80.
25. Yamashita T, Tsuji H, Maeda N, et al. Etiology of nasal polyps asso-ciated with aspirin-sensitive asthma. Rhinol Suppl 1989;8:15-24.
26. Ferreri NR, Howland WC, Stevenson DD, Spiegelberg HL. Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am Rev Respir Dis 1988;137:847-54.
27. Stevenson DD, Hankammer MA, Mathison DA, et al. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: Long-term outcomes. J Allergy Clin Immunol 1996;98:751-8.
28. McFadden EA, Woodson BT, Massaro BM, Toohill RJ. Orbital complications of sinusitis in the aspirin triad syndrome. Laryngoscope 1996;106:1103-7.
29. Kennedy DW. Prognostic factors, outcomes and staging in ethmoid sinus surgery. Laryngoscope 1992;102(Suppl 57):1-18.
30. Donnelly AL, Glass M, Minkwitz MC, Casale TB. The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 1995;151:1734-9.
31. Smith LJ, Geller S, Ebright L, et al. Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219. Am Rev Respir Dis 1990;141:988-92.
32. Spector SL, Smith LJ, Glass M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med 1994;150:618-23.
33. Israel E, Cohn J, Dube L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: A randomized controlled trial. Zileuton Clinical Trial Group. JAMA 1996;275:931-6.
34. Rubin P, Dube L, Braeckman R, et al. Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase. Agents Actions Suppl 1991;35:103-16.
35. Reiss TF, Altman LC, Munk ZM, et al. MK-0476, an LTD4 receptor antagonist, improves the signs and symptoms of asthma with a dose as low as 10 mg once daily [abstract]. Am J Respir Crit Care Med 1995;151:A378.
36. Reiss TF, Chevinsky P, Noonan M, et al. MK-0476, an LTD4 receptor antagonist, exhibits a dose-related improvement in the once-daily treatment of patients with chronic asthma [abstract]. Eur Respir J 1995;319:289.
37. Reiss TF, Chevinsky P, Edwards T, et al. Montelukast (MK-0476), a cysLTI receptor antagonist, improves the signs and symptoms of asthma over a 3-month treatment period [abstract]. Eur Respir J 1996;9:273.